In this context, our findings show that myeloid-CITED2 deficiency exacerbates HFD-induced obesity, subcutaneous and visceral fat accumulation, glucose intolerance, and insulin resistance in vivo (Figure 1A–E). Here, CITED2 is linked to Glucose intolerance.